[HTML][HTML] Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial
JP Wang, CY Wu, YC Yeh, YM Shyr, YY Wu, CY Kuo… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Objective To analyze the efficacy of gemcitabine with or without erlotinib for pancreatic
cancer, and to determine the predictive role of epidermal growth factor receptor (EGFR) and …
cancer, and to determine the predictive role of epidermal growth factor receptor (EGFR) and …
[HTML][HTML] A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer
Background Erlotinib induced skin toxicity has been associated with clinical benefit in
several tumour types. This phase II study evaluated the efficacy of erlotinib, dose escalated …
several tumour types. This phase II study evaluated the efficacy of erlotinib, dose escalated …
Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma
BACKGROUND. Erlotinib, in combination with gemcitabine, has shown clinical benefits in
pancreatic adenocarcinoma patients. The presence of EGFR mutations and increased …
pancreatic adenocarcinoma patients. The presence of EGFR mutations and increased …
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of …
G da Cunha Santos, N Dhani, D Tu, K Chin… - Cancer, 2010 - Wiley Online Library
Abstract BACKGROUND: National Cancer Institute of Canada Clinical Trials Group PA. 3
(NCIC CTG PA. 3) was a phase 3 study (n= 569) that demonstrated benefits for overall …
(NCIC CTG PA. 3) was a phase 3 study (n= 569) that demonstrated benefits for overall …
Targeting epidermal growth factor receptor–related signaling pathways in pancreatic cancer
PA Philip, MP Lutz - Pancreas, 2015 - journals.lww.com
Pancreatic cancer is aggressive, chemoresistant, and characterized by complex and poorly
understood molecular biology. The epidermal growth factor receptor (EGFR) pathway is …
understood molecular biology. The epidermal growth factor receptor (EGFR) pathway is …
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada …
MJ Moore, D Goldstein, J Hamm, A Figer… - Journal of clinical …, 2007 - ascopubs.org
Purpose Patients with advanced pancreatic cancer have a poor prognosis and there have
been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic …
been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic …
Erlotinib in the treatment of advanced pancreatic cancer
RK Kelley, AH Ko - Biologics: Targets and Therapy, 2008 - Taylor & Francis
Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy
Although erlotinib has become an important therapeutic option in addition to gemcitabine,
the high frequency of KRAS mutations in pancreatic cancer probably limits the benefits. We …
the high frequency of KRAS mutations in pancreatic cancer probably limits the benefits. We …
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
S Shin, CM Park, H Kwon, KH Lee - BMC cancer, 2016 - Springer
Background A randomized clinical trial has found that the addition of erlotinib to gemcitabine
(GEM-E) for pancreatic cancer led to a modest increase in survival. The aim of this national …
(GEM-E) for pancreatic cancer led to a modest increase in survival. The aim of this national …
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
Background It has not yet been defined if KRAS has a prognostic value or is a predictive
biomarker for the efficacy of erlotinib in advanced pancreatic cancer (PC). Methods AIO …
biomarker for the efficacy of erlotinib in advanced pancreatic cancer (PC). Methods AIO …
相关搜索
- epidermal growth factor receptor
- growth factor receptor mutations
- treatment of advanced pancreatic cancer
- cancer patients kras mutations
- clinical outcomes kras mutations
- gemcitabine alone cancer institute
- cancer patients clinical outcomes
- mutations on survival pancreatic adenocarcinoma
- erlotinib in patients objective response
- kinase mutations pancreatic adenocarcinoma